Notwithstanding this, performing PD-L1 re-determination after CRT in patient resulted PDL1 negative at the beginning, can allow offering maintenance Durvalumab to patients who otherwise could have not benefit from it, as the European Medicines Agency (EMA) has recommended Durvalumab exclusively in patients with a tumor proportion score PDL1 (TPS) ̳ 1%. The gene discussed is CD274; the disease is neoplasm.